ライフサイエンスコーパス: portal hypertension

1 redict altered risk of incident cirrhosis or portal hypertension.

2 ension (IPH) is a rare cause of intrahepatic portal hypertension.

3 giogenesis is implicated in fibrogenesis and portal hypertension.

4 ccurate noninvasive technique for estimating portal hypertension.

5 uent increased portal venous inflow leads to portal hypertension.

6 hosis, and might be a therapeutic target for portal hypertension.

7 l dysfunction in patients with cirrhosis and portal hypertension.

8 ortal inflow to contribute to development of portal hypertension.

9 ol for the diagnosis of clinically important portal hypertension.

10 asodilation, a mechanism that contributes to portal hypertension.

11 plasma-ascitic albumin gradient to diagnose portal hypertension.

12 position fails to eliminate complications of portal hypertension.

13 any signs of residual/recurrent features of portal hypertension.

14 to the arterial vasodilation associated with portal hypertension.

15 hether Nogo-B gene deletion could ameliorate portal hypertension.

16 s) modulates fibrogenesis, angiogenesis, and portal hypertension.

17 liary dysgenesis, portal tract fibrosis, and portal hypertension.

18 injury, with resultant sinusoidal damage and portal hypertension.

19 y 5) of developing severe liver disease with portal hypertension.

20 osis (CF) develops severe liver disease with portal hypertension.

21 atients with cystic fibrosis and significant portal hypertension.

22 and may be important in the pathogenesis of portal hypertension.

23 atients without liver failure or significant portal hypertension.

24 atic inflammation, fibrosis, congestion, and portal hypertension.

25 hepatorenal syndrome, or bleeding caused by portal hypertension.

26 eneficial effect of NO donors for therapy of portal hypertension.

27 progressive thrombocytopenia, suggestive of portal hypertension.

28 ntribute significantly to the development of portal hypertension.

29 bnormalities, which may lead to noncirrhotic portal hypertension.

30 patients with alcohol-related cirrhosis and portal hypertension.

31 patients with cirrhosis and complications of portal hypertension.

32 hospitalized patients with complications of portal hypertension.

33 rt and disclosed a transudate, suggestive of portal hypertension.

34 namic abnormalities typical of cirrhosis and portal hypertension.

35 parameter can be used to monitor therapy of portal hypertension.

36 gement of the complications of cirrhosis and portal hypertension.

37 namic abnormalities typical of cirrhosis and portal hypertension.

38 nosis and management of the complications of portal hypertension.

39 ology and management of the complications of portal hypertension.

40 nd control of bleeding in most patients with portal hypertension.

41 tic portosystemic shunt (TIPS) for cirrhotic portal hypertension.

42 ce to pulmonary blood flow in the setting of portal hypertension.

43 namic abnormalities typical of cirrhosis and portal hypertension.

44 roles in vascular abnormalities observed in portal hypertension.

45 ct changes, lymphadenopathy, and findings of portal hypertension.

46 nosis and management of the complications of portal hypertension.

47 namic abnormalities typical of cirrhosis and portal hypertension.

48 nosis and management of the complications of portal hypertension.

49 the injured liver and leads to intrahepatic portal hypertension.

50 ology and management of the complications of portal hypertension.

51 lular function, perisinusoidal fibrosis, and portal hypertension.

52 enerative hyperplasia (NRH) of the liver and portal hypertension.

53 he treatment of many of the complications of portal hypertension.

54 the 1980s for treatment of complications of portal hypertension.

55 ute inferior vena caval occlusion to produce portal hypertension.

56 tment attenuated burn- and endotoxin-induced portal hypertension.

57 are the earliest indicators of cirrhosis and portal hypertension.

58 lting in functional Budd-Chiari syndrome and portal hypertension.

59 ellular carcinoma (HCC), without evidence of portal hypertension.

60 odilation, which contributes to the onset of portal hypertension.

61 rhosis and liver failure but not in isolated portal hypertension.

62 eries of rats and mice with cirrhosis or/and portal hypertension.

63 lent option to treat severe complications of portal hypertension.

64 to vasodilators, with beneficial effects on portal hypertension.

65 but they do not accurately reflect degree of portal hypertension.

66 a specific cause of idiopathic noncirrhotic portal hypertension.

67 % [12 of 20]) underwent major resection with portal hypertension.

68 superior to liver elastography in predicting portal hypertension.

69 with protection against hepatic fibrosis and portal hypertension.

70 overweight/obese patients with cirrhosis and portal hypertension.

71 trary effects in cirrhotic and non-cirrhotic portal hypertension.

72 inically significant (CSPH) and severe (SPH) portal hypertension.

73 epresent risk factors for hepatic injury and portal hypertension.

74 h A, 6 Child-Pugh B, and 1 Child-Pugh C) and portal hypertension (11 males, median age 54 years (rang

75 wed by cholelithiasis in liver cirrhosis and portal hypertension (18.2%) and empyema or perforated ga

76 In 5-6% of patients with portal hypertension a pathological state exists in which

77 In addition to portal hypertension, a number of other vascular syndrome

78 al IHBDD complicated with cholangitis and/or portal hypertension achieved excellent long-term patient

79 n, AQP1 promotes angiogenesis, fibrosis, and portal hypertension after bile duct ligation and is regu

80 rization, and developed less-severe forms of portal hypertension after portal vein ligation.

81 s of human hepatopulmonary syndrome, whereas portal hypertension alone due to partial portal vein lig

82 esophageal varices result almost solely from portal hypertension, although the hyperdynamic circulati

83 esophageal varices result almost solely from portal hypertension, although the hyperdynamic circulati

84 rom 0% to 4%, 20 patients with cirrhosis and portal hypertension and 20 healthy volunteers with no kn

85 the only procedure that completely reverses portal hypertension and addresses the primary disease wh

86 es in unselected patients with cirrhosis and portal hypertension and are associated with an increased

87 04038 increases sodium excretion and reduces portal hypertension and ascites in experimental cirrhosi

88 nts and rats with cirrhosis and ascites have portal hypertension and circulatory dysfunction.

89 ns, widely accepted in vivo animal models of portal hypertension and cirrhosis, and in vitro angiogen

90 the endogenous angioinhibitor vasohibin-1 in portal hypertension and cirrhosis.

91 e a promising novel therapeutic strategy for portal hypertension and cirrhosis.

92 nsfer exerts multifold beneficial effects in portal hypertension and cirrhosis: reduction of patholog

93 nts, ductular cell expansion correlated with portal hypertension and collagen expression.

94 onse to chronic liver injury, which leads to portal hypertension and end-stage liver disease.

95 isease or for massive hemorrhage from severe portal hypertension and extensive adhesions.

96 childhood cirrhosis, increases the risks for portal hypertension and gastrointestinal bleeding.

97 nous engorgement that will contribute toward portal hypertension and gut edema.

98 reduced endothelial fenestrae and developed portal hypertension and hepatic angiosarcoma over time.

99 Two major syndromes result from cirrhosis: portal hypertension and hepatic insufficiency.

100 ife-saving therapy to correct liver failure, portal hypertension and hepatocellular carcinoma arising

101 ohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet th

102 ary prophylaxis of bleeding in children with portal hypertension and high-risk varices.

103 ress in understanding the pathophysiology of portal hypertension and improvements in the diagnosis an

104 omes were discussed in more detail including portal hypertension and IR injury.

105 Portal hypertension and its complications account for th

106 oteins CPEB1 and CPEB4 during development of portal hypertension and liver disease.

107 to biliary cirrhosis and the development of portal hypertension and liver failure occurs in a minori

108 Progressive liver fibrosis leads to portal hypertension and liver failure; however, the mech

109 sfunction contributes to the pathogenesis of portal hypertension and may represent a novel therapeuti

110 In disease models such as portal hypertension and mesenteric artery high/low flow,

111 ory function and prognosis in cirrhosis with portal hypertension and normal creatinine.

112 in patients with PSC, noninvasive markers of portal hypertension and of advanced liver disease predic

113 These patients are prone to gallstones, portal hypertension and possible surgical complications

114 irrhosis with its attendant complications of portal hypertension and potentially end-stage liver dise

115 cirrhosis complications, such as early-onset portal hypertension and primary liver cancers.

116 imaging was performed in seven patients with portal hypertension and refractory ascites before and 2

117 obtained in properly selected patients with portal hypertension and relatively spared hepatic functi

118 support in a variety of conditions including portal hypertension and senescence.

119 fects 10%-30% of patients with cirrhosis and portal hypertension and significantly increases mortalit

120 Coexisting portal hypertension and the associated risks of volume e

121 This was accompanied by early-onset severe portal hypertension and twofold to fourfold increase in

122 patients (LD rate, 28.6% [85 of 297]) had no portal hypertension and underwent major resections or, i

123 Approaches to the management of portal hypertension and variceal hemorrhage in pediatric

124 , but in a certain group of patients without portal hypertension and well-preserved liver function re

125 therapeutic option, but in patients without portal hypertension and well-preserved liver function, r

126 , but in a certain group of patients without portal hypertension and well-preserved liver function, s

127 Complications of portal hypertension and, rarely, hepatocellular carcinom

128 on PET), 1 patient had liver cirrhosis with portal hypertension, and 1 patient had a 5 cm abdominal

129 scarring from any cause leads to cirrhosis, portal hypertension, and a progressive decline in renal

130 with hepatic "recompensation," reduction of portal hypertension, and eventually avoidance of liver t

131 esulting fibrosis can lead to organ failure, portal hypertension, and fatal bleeding.

132 parenchyma, leading to hepatic dysfunction, portal hypertension, and hepatomegaly.

133 risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion us

134 nary arterial hypertension in the setting of portal hypertension, and is present in 5%-10% of cirrhos

135 hout (OR, 2.98; 95% CI, 1.97-4.52; P < .001) portal hypertension, and MELD score (OR, 1.79; 95% CI, 1

136 onalcoholic steatohepatitis, liver fibrosis, portal hypertension, and nodular regenerative hyperplasi

137 dure corrected liver function and eliminated portal hypertension, and the patient showed substantial

138 , FAH(-/-) pigs developed liver fibrosis and portal hypertension, and thus may serve as a large-anima

139 ere hepatosplenism, periportal fibrosis with portal hypertension, and urogenital inflammation and sca

140 rding the management of the complications of portal hypertension are reviewed, including a trial of b

141 rding the management of the complications of portal hypertension are reviewed, including trials that

142 The aim of this study is to evaluate portal hypertension as an independent risk factor in gen

143 patients with compensated cirrhosis and with portal hypertension as determined by the hepatic venous

144 Recursive partitioning analysis confirmed portal hypertension as the most important factor (OR, 2.

145 significant reduction of portal fibrosis and portal hypertension as well as of liver cysts.

146 s used to act on the mechanisms that lead to portal hypertension, as well as recent advances in the d

147 transfer on angiogenesis, fibrogenesis, and portal hypertension-associated hemodynamic alterations w

148 provides evidence that vasohibin-1 regulates portal hypertension-associated pathological angiogenesis

149 Only FIB-4 predicted portal hypertension at diagnosis (area under the receive

150 er cirrhosis is complicated by bleeding from portal hypertension but also by portal vein thrombosis (

151 Patients had cirrhosis and portal hypertension but did not have GEV.

152 213 subjects with compensated cirrhosis with portal hypertension but without GEV enrolled in a random

153 213 patients with compensated cirrhosis and portal hypertension but without varices included in a tr

154 fects 10%-30% of patients with cirrhosis and portal hypertension, but the impact on functional status

155 Portal hypertension can be ameliorated by percutaneous o

156 tients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the Uni

157 ality Improvement Program (NSQIP) formed the portal hypertension cohort, and were case matched to pat

158 sidered as a noninvasive technique to manage portal hypertension complications.

159 re needed to identify clinically significant portal hypertension (CSPH) and esophageal varices (EVs)

160 CLD), the presence of clinically significant portal hypertension (CSPH) and varices needing treatment

161 Whether preoperative clinically significant portal hypertension (CSPH) has or not an impact on the o

162 nty-four patients had clinically significant portal hypertension (CSPH), of whom 59 had severe portal

163 ssociated cirrhosis and clinical significant portal hypertension (CSPH, hepatic venous pressure gradi

164 t (HVPG), and predict clinically significant portal hypertension (CSPH; HVPG >/= 10 mmHg), decompensa

165 Patients with liver cirrhosis and portal hypertension demonstrated faster-than-normal tran

166 Portal hypertension did not occur in iloprost-treated an

167 llnesses include connective tissue diseases, portal hypertension, diet and stimulant drug use, HIV in

168 varices, which are most commonly a result of portal hypertension, downhill esophageal varices result

169 Cirrhosis and portal hypertension due to chronic common bile duct liga

170 ne recipients have evidence of non-cirrhotic portal hypertension due to periportal liver fibrosis or

171 c varices (GV) occur in 20% of patients with portal hypertension either in isolation or in combinatio

172 s pressure would be valuable when diagnosing portal hypertension, evaluating patient prognosis, and m

173 ediating inherited and acquired noncirrhotic portal hypertension, expand the phenotypic spectrum of D

174 rices (EVs) or having clinically significant portal hypertension (for presurgical risk stratification

175 had cirrhosis with clinical complications of portal hypertension from all patients (n = 271,030) hosp

176 The treatment options for portal hypertension have expanded greatly in the past 2

177 nrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [H

178 determined any relationship with severity of portal hypertension (hepatic venous pressure gradient me

179 onitis, the cardiopulmonary complications of portal hypertension (hepatopulmonary syndrome, portopulm

180 lity were associated with the development of portal hypertension, hepatosplenomegaly, gastrointestina

181 .1; 95% CI, 2.0 to 8.3), PAH associated with portal hypertension (HR, 3.6; 95% CI, 2.4 to 5.4), modif

182 Subjects with clinically insignificant portal hypertension (HVPG < 10 mm Hg) whose PLT remained

183 ss vary differently with respect to cause of portal hypertension (ie, congestion- or cirrhosis-induce

184 eoside analogue didanosine is known to cause portal hypertension in a subset of patients and lowers d

185 l hemorrhage is a concerning complication of portal hypertension in children, the first bleed appears

186 contributes to splanchnic vasodilatation and portal hypertension in cirrhosis.

187 etwork and are correlated to the severity of portal hypertension in cirrhosis.

188 he presence of hepatic nodules, and signs of portal hypertension in consensus.

189 Data on the impact of portal hypertension in general surgical outcomes has bee

190 increased intrahepatic resistance (IHR) and portal hypertension in NASH cirrhotic rats.

191 ; these events subsequently increase IHR and portal hypertension in NASH cirrhotic rats.

192 vein thrombosis is the most common cause of portal hypertension in noncirrhotic patients.

193 t leads to better control of RA secondary to portal hypertension in patients with cirrhosis, compared

194 lications related to liver insufficiency and portal hypertension in patients with heavy alcohol intak

195 rogeneous group of diseases characterized by portal hypertension in the absence of cirrhosis.

196 nosis and management of the complications of portal hypertension in the face of an increasing burden

197 early-onset familial idiopathic noncirrhotic portal hypertension, in which Mendelian mutations may ac

198 c topics reviewed are the pathophysiology of portal hypertension (including recent findings regarding

199 m 66 children with major endoscopic signs of portal hypertension, including grade 3 esophageal varice

200 reased risk attributable to complications of portal hypertension, including variceal rupture.

201 aimed at modifying the factors that lead to portal hypertension (increased intrahepatic vascular res

202 aimed at modifying the factors that lead to portal hypertension (increased intrahepatic vascular res

203 Portal hypertension, indicated by low platelet counts, w

204 Idiopathic portal hypertension (IPH) is a rare cause of intrahepati

205 Having complications of portal hypertension is a harbinger of decompensated cirr

206 Idiopathic noncirrhotic portal hypertension is a heterogeneous group of diseases

207 Portal hypertension is a prominent feature of advanced l

208 Gastrointestinal bleeding related to portal hypertension is a serious complication in patient

209 Portal hypertension is associated with a significant mor

210 The development of portal hypertension is fundamental in the pathogenesis o

211 re gradient (HVPG) is based on the fact that portal hypertension is pathogenically related to liver i

212 Portal hypertension is responsible for most of the compl

213 Portal hypertension is the main complication of cirrhosi

214 Portal hypertension is the result of increased intrahepa

215 Portal hypertension is the result of increased intrahepa

216 Portal hypertension is the result of increased intrahepa

217 Idiopathic EHPVT, a significant cause of portal hypertension, is surgically corrected by MRB.

218 omoting liver sinusoidal capillarization and portal hypertension, ischemic heart disease, peripheral

219 is and management of idiopathic noncirrhotic portal hypertension, its pathogenesis remains elusive.

220 lt of diffuse portomesenteric thrombosis and portal hypertension, life-threatening bleeding was unres

221 ociated with the development of noncirrhotic portal hypertension, likely owing to injury to the micro

222 portosystemic shunt (TIPS) in patients with portal hypertension may be considered as a rescue therap

223 ed with progressively developed fibrosis and portal hypertension (mean stiffness at 80 Hz and 48-week

224 t hepatic fibrogenesis and cirrhosis, marked portal hypertension, microcirculatory dysfunction, an en

225 mly assigned 213 patients with cirrhosis and portal hypertension (minimal hepatic venous pressure gra

226 Noncirrhotic portal hypertension (NCPH) is a rare but important clini

227 Noncirrhotic portal hypertension (NCPH) is a rare but potentially lif

228 nce of Nogo-B ameliorates liver fibrosis and portal hypertension, Nogo-B blockade may be a potential

229 Once portal hypertension occurred, all subjects on TG were ch

230 ght subjects from six kindreds with onset of portal hypertension of indeterminate etiology during inf

231 lustrate the potential independent effect of portal hypertension on clinical outcome outside the sett

232 To evaluate the impact of noncirrhotic portal hypertension on survival in CGD, all records from

233 ections or, in case of minor resections, had portal hypertension or a MELD score greater than 9; and

234 tio [OR], 2.41; 95% CI, 1.17-4.30; P = .01), portal hypertension (OR, 2.20; 95% CI, 1.13-4.30; P = .0

235 ephalopathy, esophageal varices, ascites, or portal hypertension) or liver transplant were estimated

236 e at risk of developing liver insufficiency, portal hypertension, or bowel infarction and may experie

237 nt may be a useful measure of progression of portal hypertension over time.

238 sence of a high-flow fistula, which elevated portal hypertension, patient did not qualify for the liv

239 the standard used to determine the degree of portal hypertension (PH) and an important prognostic fac

240 arkers would be useful for the assessment of portal hypertension (PH) and esophageal varices (EV) in

241 All patients had evidence of portal hypertension (PH) at diagnosis, and 42% were symp

242 resistance (IHVR) is the primary factor for portal hypertension (PH) development.

243 Pharmacological treatment of portal hypertension (PH) has been exclusively devoted to

244 UGIB was attributed to portal hypertension (PH) in 99 (63%) patients and peptic

245 Portal hypertension (PH) is a major cause of morbidity a

246 Portal hypertension (PH) is a recognized risk factor of

247 hosis, and the presence of clinical signs of portal hypertension (PH) were assessed using receiver op

248 Portal hypertension (PH), a pathophysiological derangeme

249 CB(2) agonist alleviates portal hypertension (PH), severity of portosystemic coll

250 sequences, including fibrosis/cirrhosis with portal hypertension (PH).

251 rs of the presence of clinically significant portal hypertension (PH).

252 logical alterations that are associated with portal hypertension (PH).

253 hosis but also portal vein obstruction cause portal hypertension (PHT) and angiogenesis.

254 ular resistance that is the primary cause of portal hypertension (PHT) in cirrhosis.

255 Portal hypertension (PHT) is associated with increased s

256 athways in different rat models of cirrhotic portal hypertension (PHT).

257 ices in those with compensated cirrhosis and portal hypertension (PHT).

258 ant discoveries about the pathophysiology of portal hypertension (PHT).

259 with preoperative hierarchic interaction of portal hypertension, planned extension of hepatectomy, a

260 anulomatous inflammation in the liver causes portal hypertension, porto-pulmonary shunting, bleeding

261 Liver cirrhosis and portal hypertension present with three unique pulmonary

262 In patients with bleeding related to portal hypertension, prophylactic antibiotics may decrea

263 within a prospective cohort of patients with portal hypertension recruited from tertiary care centers

264 oportions of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01

265 of varices and the incidence and outcome of portal hypertension-related bleeding.

266 The potential use of terutroban for portal hypertension requires further investigation.

267 ntrahepatic bile ducts + 2 x dysmorphy + 1 x portal hypertension; score with gadolinium administratio

268 mic encephalopathy, is a consequence of both portal hypertension (shunting of blood through portosyst

269 emic encephalopathy is a consequence of both portal hypertension (shunting of blood through portosyst

270 emic encephalopathy is a consequence of both portal hypertension (shunting of blood through portosyst

271 emic encephalopathy is a consequence of both portal hypertension (shunting of blood through portosyst

272 l hypertension (CSPH), of whom 59 had severe portal hypertension (SPH).

273 disease; ascites plays no role in this, but portal hypertension stiffens the gastric walls and creat

274 y, GRK2-deficient mice developed less severe portal hypertension than control mice.

275 e better control of these 2 complications of portal hypertension than standard forms of therapy.

276 nosis and management of the complications of portal hypertension that have occurred in the last year

277 osis, and management of the complications of portal hypertension that have occurred in the last year.

278 osis, and management of the complications of portal hypertension that have occurred in the past year.

279 Portal hypertension, the main complication of cirrhosis,

280 Hepatic stellate cells (HSCs) contribute to portal hypertension through multiple mechanisms that inc

281 ne age; sex; performance status; presence of portal hypertension; tumor distribution; levels of bilir

282 t survival in patients with complications of portal hypertension undergoing elective placement of tra

283 cardiography (TEE) in patients with signs of portal hypertension undergoing orthotopic liver transpla

284 rts of patients with idiopathic noncirrhotic portal hypertension undergoing TIPS in seven centers bet

285 patients (LD rate, 4.9% [11 of 226]) without portal hypertension underwent minor resection with a MEL

286 transit in patients with liver cirrhosis and portal hypertension using a magnet-based Motility Tracki

287 scular diseases and is associated with liver portal hypertension, vascular shunting, and portal fibro

288 Liver injury with portal hypertension was established using bile duct liga

289 s induced in rats by bile duct ligation, and portal hypertension was induced by partial portal vein l

290 Cirrhosis was present in 157 patients (91%); portal hypertension was present in 139 patients (81%).

291 Fibrosis and portal hypertension were attenuated based on immunostain

292 Hispanics hospitalized for complications of portal hypertension were less likely to undergo a pallia

293 rences with preserved liver function, and no portal hypertension were treated with resection.

294 unt is the best predictor of the severity of portal hypertension, which has early onset but is underd

295 In patients with idiopathic noncirrhotic portal hypertension who have normal kidney function or d

296 cutive patients with severe complications of portal hypertension who received placement of TIPS from

297 Patients with mild portal hypertension whose PLT remains greater than 100,0

298 Two rodent models of portal hypertension with increased BT were used, CCl(4)-

299 All three affected subjects had stable portal hypertension with noncirrhotic liver disease for

300 Portal hypertension with or without mesenteric vasoconst